Talaris Therapeutics Inc Stock
Talaris Therapeutics Inc Stock price
Key metrics
| Market capitalization | $609.01m |
| Enterprise Value | $327.38m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.90 |
| Dividend yield | 0.00% |
| Last dividend (FY23) | $15.12 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-78.82m |
Is Talaris Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Talaris Therapeutics Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Talaris Therapeutics Inc forecast:
Analyst Opinions
7 Analysts have issued a Talaris Therapeutics Inc forecast:
Financial data from Talaris Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -80 -80 |
-
|
EBIT (Operating Income) EBIT | -79 -79 |
-
|
| Net Profit | -64 -64 |
-
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Talaris Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.
| Head office | United States |
| CEO | Sandeep Kulkarni |
| Employees | 52 |
| Founded | 2021 |
| Website | www.tourmalinebio.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
